Amgen Inc
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$465.45−0.56 (-0.12%)
Close on Nov 2, 2026Market cap $251.64BP/E 28.9Yield 2.08%
Amgen Commercial Paper Program by Year
Commercial Paper Program — Maximum Authorized Capacity ($M) ($M)
Amgen Commercial Paper Program: $4,000M in FY2025, up 60.0% from a year earlier. That is the highest of the 8 years on record here.
Latest, FY2025
4,000
Period ended Dec 31, 2025
Change on a year earlier
+60.0%
2,500 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Where the FY2025 figure comes from
Source: Form 10-K (filed 2026-02-13) ↗
Reported in Form 10-Q / 10-K Financing Arrangements Note (XBRL).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Commercial Paper Program — Maximum Authorized Capacity ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4,000 | +60.0% | Form 10-K (filed 2026-02-13) ↗ |
| FY2024 | Dec 31, 2024 | 2,500 | 0.0% | Form 10-K (filed 2025-02-14) ↗ |
| FY2023 | Dec 31, 2023 | 2,500 | 0.0% | Form 10-K (filed 2024-02-14) ↗ |
| FY2022 | Dec 31, 2022 | 2,500 | 0.0% | Form 10-K (filed 2023-02-09) ↗ |
| FY2021 | Dec 31, 2021 | 2,500 | 0.0% | Form 10-K (filed 2022-02-16) ↗ |
| FY2020 | Dec 31, 2020 | 2,500 | 0.0% | Form 10-K (filed 2021-02-09) ↗ |
| FY2019 | Dec 31, 2019 | 2,500 | 0.0% | Form 10-K (filed 2020-02-12) ↗ |
| FY2018 | Dec 31, 2018 | 2,500 | – | Form 10-K (filed 2019-02-13) ↗ |
Cite this data
StockData. (2026). Amgen Commercial Paper Program ($M), annual FY2018–FY2025 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/cp-max-cap
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.